<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Excessive <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> contribute to the pathogenesis of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>MFG-E8 is a 66-kDa <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> that has shown tissue protection in various models of organ injury </plain></SENT>
<SENT sid="2" pm="."><plain>However, the potential role of MFG-E8 in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> has not been investigated </plain></SENT>
<SENT sid="3" pm="."><plain>We found that levels of MFG-E8 protein in the brain were reduced at 24 h after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>To assess the potential role of MFG-E8 in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, adult male Sprague-Dawley rats were subjected to permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="5" pm="."><plain>At 1 h post-<z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo>, an intravenous administration of 1 ml saline as vehicle or 160 μg/kg BW recombinant human MFG-E8 (rhMFG-E8) as treatment was given </plain></SENT>
<SENT sid="6" pm="."><plain>The optimal dose of rhMFG-E8 was obtained from previous dose-response organ protection in rat <z:hpo ids='HP_0100806'>sepsis</z:hpo> studies </plain></SENT>
<SENT sid="7" pm="."><plain>Neurological scores were determined at 24 h and 48 h post-MCAO </plain></SENT>
<SENT sid="8" pm="."><plain>Rats were sacrificed thereafter and brains rapidly removed and analyzed for <z:mpath ids='MPATH_124'>infarct</z:mpath> size, histopathology, and markers of <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>Compared with saline vehicle, rhMFG-E8 treatment led to significant decreases in sensorimotor and vestibulomotor deficits, and <z:mpath ids='MPATH_124'>infarct</z:mpath> size at 24 h and 48 h post-MCAO </plain></SENT>
<SENT sid="10" pm="."><plain>Measures associated with improved outcome included reduced microglial inflammatory cytokine secretion, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules and neutrophil influx, cleaved caspase-3, and upregulation of peroxisome proliferator activated receptor-γ (PPAR-γ), and Bcl-2/Bax ratio leading to <z:mp ids='MP_0006043'>decreased apoptosis</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>Thus, rhMFG-E8 treatment is neuroprotective against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> through suppression of <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="12" pm="."><plain>This article is part of a Special Issue entitled '<z:e sem="disease" ids="C0038436" disease_type="Mental or Behavioral Dysfunction" abbrv="PTSD">Post-Traumatic Stress Disorder</z:e>' </plain></SENT>
</text></document>